Valneva SE - Company Profile
Powered by
All the data and insights you need on Valneva SE in one report.
- Save hours of research time and resources with
our up-to-date Valneva SE Strategy Report
- Understand Valneva SE position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Valneva SE (Valneva) is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of Lyme disease, Zika virus, Chikungunya and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and distribute its products. The company sells its products in the Americas, Asia-Pacific, Europe, and the Middle East. It operates in Austria, Sweden, the UK, France, the US, and Canada. Valneva is headquartered in Saint-Herblain, France.
Valneva SE premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Ixiaro/Jespect- Japanese Encephalitis Vaccine | Distribution Services for Third-Party's Products | IXIARO/JESPECT |
Dukoral- Cholera Vaccine | DUKORAL | |
Pipeline | JEVAL | |
XYZ | ||
XYZ | ||
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In August, the company entered into an agreement with funds managed by Deerfield Management Company and OrbiMed to increase the principal amount of US$100 million. |
2022 | Contracts/Agreements | In September, the company and VBI Vaccines Inc entered into a partnership for the marketing and distribution of PreHevbri. |
2022 | Contracts/Agreements | In August, the company and Pfizer announced the initiation of a phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. |
Competitor Comparison
Key Parameters | Valneva SE | Astellas Pharma Inc | bioMerieux SA | Dynavax Technologies Corp | Innate Pharma SA |
---|---|---|---|---|---|
Headquarters | France | Japan | France | United States of America | France |
City | Saint-Herblain | Chuo-Ku | Craponne | Emeryville | Marseille |
State/Province | Lorraine | Tokyo | Rhone Alpes | California | Bourgogne |
No. of Employees | 700 | 14,484 | 13,842 | 408 | 191 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Thomas Lingelbach | Chief Executive Officer; President | Executive Board | 2013 | 59 |
Franck Grimaud | Chief Business Officer; Director - General | Executive Board | 2013 | 56 |
Peter Buhler | Chief Financial Officer | Senior Management | 2022 | - |
Juan Carlos Jaramillo, M.D. | Chief Medical Officer | Senior Management | 2020 | 52 |
Dipal Patel | Chief Commercial Officer | Senior Management | 2022 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward